Exane BNP Paribas analyst Sylvain Brunet upgrades Vale (NYSE:VALE) from Underperform to Neutral.
Stifel Upgrades IDEAYA Biosciences to Buy, Lowers Price Target to $20
Stifel analyst Benjamin Burnett upgrades IDEAYA Biosciences (NASDAQ:IDYA) from Hold to Buy and lowers the price target from $27 to $20.